Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.

Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C, Helman LJ.

Cancer Res. 2008 Oct 1;68(19):8039-48. doi: 10.1158/0008-5472.CAN-08-1712.

2.

Molecular characterization of pediatric gastrointestinal stromal tumors.

Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2008 May 15;14(10):3204-15. doi: 10.1158/1078-0432.CCR-07-1984.

3.

IGF2: epigenetic regulation and role in development and disease.

Chao W, D'Amore PA.

Cytokine Growth Factor Rev. 2008 Apr;19(2):111-20. doi: 10.1016/j.cytogfr.2008.01.005. Epub 2008 Mar 4. Review.

4.

Monoclonal antibodies against components of the IGF system for cancer treatment.

Feng Y, Dimitrov DS.

Curr Opin Drug Discov Devel. 2008 Mar;11(2):178-85. Review.

PMID:
18283605
5.

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA.

Pediatr Blood Cancer. 2008 Jun;50(6):1190-7. doi: 10.1002/pbc.21450.

PMID:
18260118
6.
7.

Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors.

Bjornsson HT, Brown LJ, Fallin MD, Rongione MA, Bibikova M, Wickham E, Fan JB, Feinberg AP.

J Natl Cancer Inst. 2007 Aug 15;99(16):1270-3. Epub 2007 Aug 8.

8.

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force.

J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30. Review. Erratum in: J Natl Compr Canc Netw. 2007 Aug;5(7):xxx.

PMID:
17624289
9.

Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2.

Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV.

Cell Cycle. 2007 Mar 15;6(6):705-13. Epub 2007 Mar 20. Review.

PMID:
17374994
10.
11.

Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.

Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A.

Clin Cancer Res. 2007 Feb 1;13(3):1000-9.

12.

Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report.

Shevah O, Laron Z.

Growth Horm IGF Res. 2007 Feb;17(1):54-7. Epub 2006 Dec 12.

PMID:
17166755
13.

Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.

Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler MA, Dome JS, Grundy PE, Vujanic GM, Pritchard-Jones K, Jones C.

Cancer Res. 2006 Dec 1;66(23):11148-55.

14.

Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.

Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, Raschellà G.

Clin Cancer Res. 2006 Nov 15;12(22):6772-80.

15.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

Lancet. 2006 Oct 14;368(9544):1329-38.

PMID:
17046465
16.

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

Wan X, Harkavy B, Shen N, Grohar P, Helman LJ.

Oncogene. 2007 Mar 22;26(13):1932-40. Epub 2006 Sep 25.

PMID:
17001314
17.

RNA interference for the treatment of cancer.

Putral LN, Gu W, McMillan NA.

Drug News Perspect. 2006 Jul-Aug;19(6):317-24. Review.

PMID:
16971967
18.

Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma.

Owen LA, Lessnick SL.

Cell Cycle. 2006 Sep;5(18):2049-53. Epub 2006 Sep 15. Review.

PMID:
16969112
19.

Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.

Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL, de Alava E.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40.

20.

Supplemental Content

Support Center